Business
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 - - 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with
About this update from Immuneering Corporation
[{"type":"image","alt":"Immuneering Corporation","displaySize":"","headline":null,"caption":"Immuneering Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/0b858d23fa378250fb0126249c47625c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/soL0WMy1eyfRS2pEhmbQlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/0b858d23fa378250fb0126249c47625c","width":300,"height":59},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/soL0WMy1eyfRS2pEhmbQlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/0b858d23fa378250fb0126249c47625c","width":300,"height":59}},"lazy":false},{"type":"text","content":"- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - ","length":187,"tagName":"p"},{"type":"text","content":"- Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 - ","length":182,"tagName":"p"},{"type":"text","content":"- 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden –","length":171,"tagName":"p"},{"type":"text","content":"- Ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 -","length":123,"tagName":"p"},{"type":"text","content":"NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.","length":300,"tagName":"p"},{"type":"text","content":""We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral presentation at the ASCO Annual Meeting on June 1st,” said Ben Zeskind, Chief Executive Officer of Immuneering. “We believe the upcoming presentation at ASCO is an excellent opportunity to build...